ATLANTA — Hemophilia researchers representing Roche (RHBBY) and BioMarin Pharmaceuticals (BMRN) shared a dais Saturday during a media briefing at the American Society of Hematology (ASH) annual meeting. That’s fitting because both companies are working to disrupt the current standard of care for people living with the rare, inherited blood-clotting disorder.

With the newly approved clotting treatment Hemlibra, Roche has already put the hemophilia A businesses of Shire (SHPG) and Bioverativ (BIVV) at risk. In a few years, a promising and potentially curative gene therapy from BioMarin might do the same to Roche.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy